

# TG 292 on Electronic Brachytherapy Dosimetry: Current Status

Wesley Culberson, PhD, DABR

Department of Medical Physics, University of Wisconsin – Madison

July 30, 2018





# Disclosures

- None

# Background / Rationale

- The last decade has seen a surge of eBT manufacturers and available applicators
- Each applicator can affect the resulting dose distribution in dramatic ways
- Each system with its own unique set of calibration tools, procedures and QA systems
- There exists minimal traceability to primary standards

# Applicators

- Bare or in applicator
- Xoft balloon, vaginal, and cervical
- Zeiss INTRABEAM spherical



# Background / Rationale

- No formal recommendations of the AAPM for dosimetry standards, formalisms, or adaptations of existing protocols for eBT
- Very few details on how to perform dosimetry measurements
- No electronic brachytherapy sources on the Brachytherapy Source Registry
- No other Task Groups for eBT dosimetry (except for TG 253 – Fulkerson presentation)












# Task Group Formation

- Initial proposal submitted to the Working Group on Brachytherapy Dosimetry (WGBD) in February, 2015
  - TG292 -> WGBD -> BTSC -> TPC -> Science Council
- Approved by TPC in November, 2016
- Sunset date: December, 2019

# Task Group Members

All 10 members have experiences with electronic brachytherapy dosimetry

- Wesley Culberson (chair)
- Mark Rivard (vice chair)
- Stephen Davis
- Grace Gwe-Ya Kim
- Jessica Lowenstein
- Michael Mitch
- Zoubir Ouhib
- Marija Popovic
- Timothy Waldron
- Habib Safigholi
- Samantha Simiele

VOTING Appointments		There are 9 voting members.	
	Wesley S. Culberson, PhD wsculberson@wisc.edu 10/27/2016 - 12/31/2019 Task Group Chair		Stephen D. Davis, PhD StephenDa@baptisthealth.net 10/27/2016 - 12/31/2019 Member
	Grace Gwe-Ya Kim, PhD gweyakim@gmail.com 10/27/2016 - 12/31/2019 Member		Jessica R. Lowenstein, MS jlowenst@mdanderson.org 10/27/2016 - 12/31/2019 Member
	Michael G. Mitch, PhD michael.mitch@nist.gov 10/27/2016 - 12/31/2019 Member		Zoubir Ouhib, MS zouhib@brrh.com 10/27/2016 - 12/31/2019 Member
	Marija Popovic, PhD marija.popovic@mcgill.ca 10/27/2016 - 12/31/2019 Member		Mark J. Rivard, PhD mark.j.rivard@gmail.com 10/27/2016 - 12/31/2019 Task Group Vice Chair
	Timothy J. Waldron, MS tim-waldron@uiowa.edu 10/27/2016 - 12/31/2019 Member		
NON-VOTING Appointments		There are 2 non-voting members and guests.	
	Habib Safigholi, PhD safigholi@gmail.com 10/27/2016 - 12/31/2019 Member (nonvoting)		Samantha J. Simiele, PhD ssimiele@med.umich.edu 10/27/2016 - 12/31/2019 Member (nonvoting)

# Official Charges

For the interstitial, intracavitary, and intraluminary applications of electronic brachytherapy this Task Group will:

1. Review the approaches to electronic brachytherapy including:
  - a. The various sources and applicators currently approved and marketed including the physical characteristics and differences from radionuclide-based brachytherapy modalities.
  - b. The currently used methods of source output verification and dose calculations.
2. Develop recommendations for electronic brachytherapy dosimetry including:
  - a. A modified TG formalism.
  - b. A NIST-traceability for electronic brachytherapy source strength determination.
  - c. Appropriate methods to measure and calculate dose distributions surrounding the sources.
  - d. A description of the dosimetric effect when combining applicators with electronic brachytherapy sources.
  - e. The inclusion on the AAPM-IROC Houston Brachytherapy Source Registry






# Task Group Considerations

- TG 292 should work with the two other eBT Task Groups (TG 182 and TG 253), already in motion
- Should consider all manufacturers equally when making recommendations
- Risk-based analyses must be addressed

# Systems Under Consideration

- Two systems being considered
- (Note that other eBT systems, such as Nucletron Esteya, are for surface applications only)



Xoft Axxent

Zeiss INTRABEAM

# Systems Under Consideration

- Similarities
  - X-ray tube potentials very similar (50 kVp)
  - Both used for IORT in a variety of applicators
- Differences
  - Cooling systems (Xoft uses circulating coolant)
  - Steering (INTRABEAM system requires checks of e-beam steering)
  - Output monitoring
    - Xoft uses a well-type ionization chamber
    - INTRABEAM uses a parallel-plate based *Probe Adjuster and Ion Chamber holder* (PAICH)
  - Completely different sets of routine QA tests



# Current Approaches

- Dosimetry based on manufacturer recommendations
  - Xoft Axxent based on TG-43 formalism

$$\dot{D}(r, \theta) = S_K \cdot \Lambda \cdot \frac{G_L(r, \theta)}{G_L(r_o, \theta_o)} \cdot g_L(r) \cdot F(r, \theta)$$

Formalism initially recommended by Xoft

$$= \dot{K}_{50cm} \cdot \chi \cdot \frac{G_L(r, \theta)}{G_L(r_o, \theta_o)} \cdot g_L(r, \theta) \cdot F(r, \theta)$$

Formalism currently recommended by Xoft

- Zeiss Intrabeam based on TG-61 formalism

$$D_w^{\bullet}(r) \left[ \frac{\text{Gy}}{\text{min}} \right] = N_k \left[ \frac{\text{Gy}}{\text{C}} \right] \cdot Q(r) [\text{C}] \cdot \frac{T[\text{K}]}{T_0[\text{K}]} \cdot \frac{P_0[\text{hPa}]}{P[\text{hPa}]} \cdot k_Q \cdot k_{\text{Ka} \rightarrow \text{Dw}} \cdot 1 \left[ \frac{1}{\text{min}} \right]$$

# Current Approaches

- Although both systems use air-kerma as the metric for source output, they have very different methods of determining the absorbed dose rate to water

# The Xoft Approach

- In general terms
  - The Xoft approach is to determine the air kerma directly from the source and then utilize a single conversion coefficient from air kerma to absorbed dose to water at 1 cm from the source

$$\begin{aligned}\dot{D}(r, \theta) &= S_K \cdot \Lambda \cdot \frac{G_L(r, \theta)}{G_L(r_o, \theta_o)} \cdot g_L(r) \cdot F(r, \theta) \\ &= \dot{K}_{50cm} \cdot \chi \cdot \frac{G_L(r, \theta)}{G_L(r_o, \theta_o)} \cdot g_L(r, \theta) \cdot F(r, \theta)\end{aligned}$$

- From this location, the dose to other locations is scaled very similarly as in the TG-43 approach

# The Intrabeam Approach

- In general terms
  - Standard PSDL-traceable air-kerma calibrations are provided for a small ion chamber (PTW 34013 – 0.005cc)
  - Calibration coefficients are then corrected for the presumed source x-ray spectrum
  - Air kerma to absorbed dose to water conversions are provided

$$\dot{D}_w(r) \left[ \frac{\text{Gy}}{\text{min}} \right] = N_k \left[ \frac{\text{Gy}}{\text{C}} \right] \cdot Q(r) [\text{C}] \cdot \frac{T[\text{K}]}{T_0[\text{K}]} \cdot \frac{P_0[\text{hPa}]}{P[\text{hPa}]} \cdot k_Q \cdot k_{\text{Ka} \rightarrow \text{Dw}} \cdot 1 \left[ \frac{1}{\text{min}} \right]$$

# User Measurements



- For the Xoft system, the user measures the source output in a calibrated well-type ionization chamber with customized insert





# User Measurements

- For the INTRABEAM system, the user measures the absorbed dose rate in water using a specialized water tank



images from  
INTRABEM Water  
Phantom Manual, V5.0

# Traceable Quantities



Air kerma rate is traceable quantity for both systems

$$\begin{aligned} \dot{D}(r, \theta) &= S_K \cdot \Lambda \cdot \frac{G_L(r, \theta)}{G_L(r_0, \theta_0)} \cdot g_L(r) \cdot F(r, \theta) \\ &= \dot{K}_{50cm} \cdot \lambda \cdot \frac{G_L(r, \theta)}{G_L(r_0, \theta_0)} \cdot g_L(r, \theta) \cdot F(r, \theta) \end{aligned}$$

$$\dot{D}_w(r) \left[ \frac{\text{Gy}}{\text{min}} \right] = N_k \left[ \frac{\text{Gy}}{\text{C}} \right] \cdot Q(r) [\text{C}] \cdot \frac{T[\text{K}]}{T_0[\text{K}]} \cdot \frac{P_0[\text{hPa}]}{P[\text{hPa}]} \cdot k_Q \cdot k_{Ka \rightarrow Dw} \cdot 1 \left[ \frac{1}{\text{min}} \right]$$

# Traceable Quantities

- Xoft Axxent air-kerma rate is traceable to NIST



Lamperti free-air chamber  
(images from [www.nist.gov](http://www.nist.gov))

# Traceable Quantities

- Zeiss INTRABEAM air-kerma rates are indirectly traceable to standard x-ray beam series

	Beam quality	HVL mmAl
PTW	TW 50	1.13
PTW	TW 30	0.44
UW ADCL	UW50-L	0.79
UW ADCL	UW40-L	0.53
 INTRABEAM	50 Kvp	0.64




Figure 4. Simulated INTRABEAM 50 kV<sub>p</sub> photon spectra in air for source model parameters taken from Yanch and Harte (see table 1) and Nwankwo *et al.* Spectra are normalised to the area under the curve.




Figure 3. T-series kV reference photon beam spectra provided at PTB. These spectra were measured in air at 30 cm source-to-detector distance. Courtesy of Ludwig Buermann.



# Additional QA Tests

- In addition to the output measurements, a host of other QA tasks are recommended for each system
- For INTRABEAM system, the source alignment needs to be verified before use
  - multi-location diode system used
- “Internal radiation monitor” used to monitor output during treatment for the INTRABEAM system

# Task Group Challenges

- Developing a complete understanding of the current formalisms and associated uncertainties
- New source models
  - Xoft Axxent S700 -> S7601
- New relevant publications
  - Several publications on Zeiss Intrabeam dosimetry since inception of TG 292, including one this month!

# Task Group 292 Status

- Writing assignments delineated
- Gathering information on current approaches to eBT dosimetry
- Working with manufacturers (Xoft and Zeiss) to ensure complete understanding of the current methods

# Recommendations

- No recommendations have been finalized by the group
- The goal is to be sensitive to current paradigms, but also provide clear recommendations for clinical users and researchers moving forward
- The Brachytherapy Source Registry will be considered





Sunset date Dec 31, 2019

# Acknowledgements

- TG 292 Members
- Tom Rusch and Linda Kelly from Xoft
- Frank Weigand from Zeiss

## Questions?

